ClinicalTrials.gg
RecruitingNCT07738523CAFIBUpdated Jul 31, 2026

Caffeine Consumption and Rate Control in Permanent Atrial FIBrillation: The CAFIB Trial

A Phase 2/3 interventional study of Dietary Caffeine Intake in Atrial Fibrillation (AF), Permanent Atrial Fibrillation and Coffee Consumption, sponsored by Hospital Universitario Getafe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Hospital Universitario Getafe · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.

Planned enrollment
148th of 162
50 · median 304
Started
2026
with 9 others
Phase 2/3
2 of 247
1 open now
Primary completion
2027-12
later than 56 of 75 live
Registered
245th of 247
by date

Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 148th largest by planned enrollment of the 162 interventional ones that give a count, is one of 10 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 56 of the 75 other live ones, and was the 245th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Atrial Fibrillation with a site in Spain, or all of them as a file.
02

Study summary

The CAFIB trial is a multicenter, randomized, open-label, crossover clinical trial designed to determine whether habitual caffeine consumption in coffe adversely affects rate control in patients with permanent atrial fibrillation (AF).

The rationale stems from the discrepancy between traditional clinical recommendations, which often advise patients with arrhythmias to avoid caffeine, and the growing body of evidence suggesting that moderate coffee consumption is not associated with an increased risk of AF and may even confer cardiovascular benefits. However, no randomized study has specifically investigated this issue in patients with permanent AF, a population in whom rate control remains the cornerstone of management.

The primary hypothesis is that continued moderate caffeine consumption is non-inferior to caffeine abstinence regarding 24-hour mean heart rate control.

Participants will be randomly assigned in a 1:1 ratio to one of two treatment sequences stratified according to baseline coffee intake (1 cup/day vs. >1 cup/day). Owing to the nature of the intervention, the study is open-label; nevertheless, Holter recordings will be analyzed by blinded investigators, and the statistical analysis will also be performed blinded to treatment allocation to minimize bias.

Eligible participants are adults with permanent AF diagnosed for more than three months, stable ventricular rate control (\<110 bpm at rest), unchanged rate-control medication for at least two months, and habitual coffee consumption of at least one caffeinated cup per day. Patients with advanced heart failure, recent major cardiovascular events, cognitive impairment, implanted cardiac pacing devices, or other conditions likely to interfere with study outcomes are excluded.

The intervention compares two dietary strategies: continuation of regular caffeinated coffee consumption (at least one cup daily) versus complete caffeine abstinence, while allowing decaffeinated coffee. Energy drinks are prohibited in both groups, and participants assigned to abstinence are advised to avoid compensatory caffeine intake from other sources. No washout period is planned between crossover phases because caffeine has a biological half-life of less than 24 hours. Adherence will be assessed using caffeine consumption diaries and structured interviews at each study visit.

The primary endpoint s the 24-hour mean heart rate measured by ambulatory Holter electrocardiography. Secondary endpoints include changes in mean HR from baseline, percentage of time with HR >110 bpm or \<50 bpm, ventricular ectopic burden, symptom severity assessed using the modified EHRA classification, quality of life evaluated with the AFEQT questionnaire, circulating biomarkers of heart failure, adverse events, and changes in concomitant medical therapy.

Patients will undergo three scheduled visits (baseline, 30 days, and 60 days), each including clinical assessment, ECG, 24-hour Holter monitoring, blood sampling, and quality-of-life questionnaires.

Sample size calculation was based on detecting a clinically relevant difference of 5 bpm, assuming a standard deviation of 7 bpm, 80% statistical power, and a two-sided α of 0.05. After accounting for an anticipated 25% dropout rate and potential protocol deviations, a total of 50 patients (25 per treatment sequence) will be recruited. The primary analysis will follow the intention-to-treat principle, complemented by a per-protocol analysis. Statistical models will adjust for clinically relevant covariates, including age, sex, baseline heart rate, and concomitant rate-control therapy, while multivariable regression analyses will explore predictors of optimal heart rate control.

The protocol acknowledges several limitations, including its open-label design, reliance on self-reported caffeine intake to assess adherence, interindividual variability in caffeine metabolism, and limited external validity to stable, habitual coffee consumers with permanent AF. Despite these limitations, CAFIB represents the first randomized trial specifically evaluating the impact of caffeine consumption on ventricular rate control in permanent AF.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Permanent Atrial Fibrillation
  • Coffee Consumption
  • Caffeine Abuse

Browse trials for

Keywords

  • Atrial fibrillation
  • Coffee
  • Caffeine
  • Heart Rate
  • Permanent Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Permanent atrial fibrillation diagnosed for more than 3 months.
  • Stable rate-control status, defined as a resting heart rate \<110 bpm without changes in rate-control medication during the previous 2 months.
  • Habitual caffeine consumption (≥1 cup/day of caffeinated coffee).
  • Willingness to participate in the study, including acceptance of complete caffeine abstinence for up to two months if assigned to the abstinence arm.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years or >80 years.
  • Previous diagnosis of cognitive impairment or dementia.
  • Legal incapacity or inability to provide .
  • Inability to understand or complete quality-of-life questionnaires.
  • Presence of a cardiac implantable electronic device with pacing capability (pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device).
  • Previous successful atrioventricular node ablation.
  • Decompensated heart failure ( class III-IV) or hospitalization for heart failure within the previous 3 months.
  • Acute coronary syndrome within the previous 3 months.
  • Stroke within the previous 3 months.
  • Cardiac surgery within the previous 3 months.
  • Severe unrepaired valvular heart disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Continuation of regular caffein consumption

    Patients will continue with their usual caffeine intake. Energy drinks intakes are prohibited.

    Dietary Supplement: Dietary Caffeine Intake

  • No intervention
    Complete caffeine abstinence

    Complete caffeine abstinence, while allowing decaffeinated coffee. Energy drinks are prohibited.

Interventions

  • Dietary supplementDietary Caffeine Intake

    Patients will mantain their usual caffeine consumption

06

What researchers measure

Primary outcomes

  1. Mean Heart Rate (bpm)

    Mean Heart Rate (bpm) in 24-h Holter-ECG

    Time frame: 30 ± 5 days

Secondary outcomes

  1. Difference with baseline heart rate

    Mean difference between baseline and follow up heart rate (bpm)

    Time frame: 30 ± 5 days

  2. Symptoms Asessment

    Changes in Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire. Scores ranged 0-100. 0 represents the worst quality of life and 100 the best.

    Time frame: 30 ± 5 days

  3. Adverse Events

    Incidence of new emergency department visit due to atrial fibrillation, heart failure, acute coronary syndrome, stroke or systemic embolism.

    Time frame: 30 ± 5 days

Other outcomes

  1. Changes in rate-control medication

    Changes in rate-control medication (including betablockers, calcium channel blockers, digoxin or amiodarone)

    Time frame: 30 ± 5 days

  2. Premature Ventricular contraction burden

    Absolute and relative (%) burden of premature ventricular contractions in 24-h Holter-ECG

    Time frame: 30 ± 5 days

07

Study locations

1 of 1 sites recruiting
  • Getafe University Hospital
    Getafe, Madrid 28905, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2026
First posted
Jul 31, 2026
StartEst.
Jul 27, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 30, 2028
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07738523
Lead sponsor
Hospital Universitario Getafe
Collaborators
Instituto de Investigación Sanitaria Getafe
Responsible party
Martín Negreira Caamaño, MD, PhD (Cardiology Department, Getafe University Hospital, Spain, Hospital Universitario Getafe) — Principal investigator
First posted
Jul 31, 2026
Start date
Jul 27, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Martín Negreira-Caamaño, MD, PhD
Contact
martin.negcam@gmail.com
+34 916839360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion